NCT05304715View on ClinicalTrials.gov

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

June 4, 2023

Study Completion Date

June 4, 2023

Conditions
Clostridioides Difficile InfectionStool MicrobiomeOrgan Dysfunction SyndromeClostridioides Difficile Infection RecurrenceMortality
Interventions
DRUG

Bezlotoxumab

Single intravenous infusion of bezlotoxumab

DRUG

Normal saline 0.9% or 5% dextrose water

Single intravenous infusion - Placebo arm

Trial Locations (11)

10918

1st Department of Internal Medicine, THRIASIO General Hospital of Eleusis, Athens

2nd Department of Internal Medicine, Thriasio General Hospital, Athens

11527

1st University Department of Internal Medicine, LAIKO General Hospital of Athens,, Athens

1st University Department of Propaedeutic Surgery, IPPOKRATEION General Hospital, Athens

12462

4th Department of Internal Medicine, Attikon University Hospital, Athens

18536

2nd Department of Internal Medicine, Tzanneion General Hospital, Piraeus

26504

Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Pátrai

41334

Department of Internal Medicine, Larissa University Hospital, Larissa

45500

1st Department of Internal Medicine, General University Hospital of Ioannina, Ioannina

54621

1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloniki

68100

2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupoli

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER